[1]刘 刚.哌拉西林钠他唑巴坦钠联合盐酸莫西沙星氯化钠注射液治疗慢性阻塞性肺疾病伴急性下呼吸道感染的临床疗效[J].医学信息,2026,39(02):101-105.[doi:10.3969/j.issn.1006-1959.2026.02.018]
　LIU Gang.Clinical Efficacy of Piperacillin Sodium and Tazobactam Sodium Combined with Moxifloxacin Hydrochloride and Sodium Chloride Injection in the Treatment of Chronic ObstructivePulmonary Disease with Acute Lower Respiratory Tract Infection[J].Journal of Medical Information,2026,39(02):101-105.[doi:10.3969/j.issn.1006-1959.2026.02.018]
点击复制

哌拉西林钠他唑巴坦钠联合盐酸莫西沙星氯化钠注射液治疗慢性阻塞性肺疾病伴急性下呼吸道感染的临床疗效()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年02期
页码:
101-105
栏目:
临床证据信息
出版日期:
2026-01-15

文章信息/Info

Title:
Clinical Efficacy of Piperacillin Sodium and Tazobactam Sodium Combined with Moxifloxacin Hydrochloride and Sodium Chloride Injection in the Treatment of Chronic ObstructivePulmonary Disease with Acute Lower Respiratory Tract Infection
文章编号:
1006-1959（2026）02-0101-05
作者:
刘 刚
奉新县人民医院药剂科，江西 奉新 330700
Author(s):
LIU Gang
Pharmacy Department of Fengxin County People′s Hospital, Fengxin 330700, Jiangxi, China
关键词:
急性下呼吸道感染; 慢性阻塞性肺疾病; 哌拉西林钠他唑巴坦钠; 盐酸莫西沙星氯化钠注射液
Keywords:
Acute lower respiratory tract infection;  Chronic obstructive pulmonary disease;  Piperacillin sodium and tazobactam sodium;  Moxifloxacin hydrochloride and sodium chloride injection
分类号:
R562
DOI:
10.3969/j.issn.1006-1959.2026.02.018
文献标志码:
A
摘要:
目的 评估在慢性阻塞性肺疾病伴急性下呼吸道感染患者中应用哌拉西林钠他唑巴坦钠+盐酸莫西沙星氯化钠注射液治疗的作用。方法 按照随机数字表法将奉新县人民医院2024年3月-9月收治的60例慢性阻塞性肺疾病伴急性下呼吸道感染患者分为对照组（30例）和研究组（30例）。对照组使用盐酸莫西沙星氯化钠注射液治疗，研究组采取哌拉西林钠他唑巴坦钠+盐酸莫西沙星氯化钠注射液治疗。比较两组治疗效果、临床症状恢复情况（体温恢复时间、咳嗽消退时间、咽痛消退时间、肺部啰音消退时间）、炎性因子[C反应蛋白（CRP）、白细胞介素-6（IL-6）]、肺功能指标[第1秒用力呼气量（FEV1）、用力肺活量（FVC）、一秒率（FEV1/FVC）]。结果 与对照组相比，研究组治疗后总有效率更高（P＜0.05）。与对照组相比，研究组患者的临床症状恢复情况更优（P＜0.05）。治疗后，研究组炎性因子水平均低于对照组（P＜0.05）。研究组肺功能优于对照组（P＜0.05）。结论 在慢性阻塞性肺疾病伴急性下呼吸道感染患者治疗中，应用哌拉西林钠他唑巴坦钠+盐酸莫西沙星氯化钠注射液的效果确切，该方案能够改善患者的临床症状，降低炎性因子水平，提升肺功能，值得临床应用。
Abstract:
Objective To investigate the clinical efficacy of piperacillin sodium and tazobactam sodium combined with moxifloxacin hydrochloride and sodium chloride injection in the treatment of chronic obstructive pulmonary disease with acute lower respiratory tract infection. Methods A random number table was used to assign 60 patients with chronic obstructive pulmonary disease and acute lower respiratory tract infection, admitted to Fengxin County People’s Hospital from March to September 2024, into a control group and a study group, each containing 30 patients. The control group was treated with moxifloxacin hydrochloride and sodium chloride injection, and the study group was treated with piperacillin sodium and tazobactam sodium+moxifloxacin hydrochloride and sodium chloride injection. The treatment effect, clinical symptom recovery (body temperature recovery time, cough regression time, sore throat regression time, pulmonary rale regression time), inflammatory factors [C-reactive protein (CRP), interleukin-6 (IL-6)], pulmonary function indexes [forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced expiratory volume in one second/forced vital capacity (FEV1/FVC)] were compared between the two groups. Results The total effective rate of treatment in the study group was higher than that in the control group (P<0.05). The recovery of clinical symptoms in the study group was better than that in the control group (P<0.05). After treatment, the levels of inflammatory factors in the study group were lower than those in the control group (P<0.05). The pulmonary function of the study group was better than that of the control group (P<0.05). Conclusion Piperacillin sodium and tazobactam sodium combined with moxifloxacin hydrochloride and sodium chloride injection is effective in the treatment of chronic obstructive pulmonary disease with acute lower respiratory tract infection, which can improve the clinical symptoms, reduce the level of inflammatory response and improve the pulmonary function. It is worthy of clinical application.

参考文献/References:

[1]徐敏,胡岗,刘晓,等.头孢哌酮/舒巴坦联合莫西沙星治疗COPD合并急性下呼吸道感染临床疗效及对血清相关因子的影响[J].西部医学,2019,31(3):416-421[2]韩柳,刘威.微生态制剂联合莫西沙星序贯疗法对老年慢性阻塞性肺疾病合并下呼吸道感染患者肠道菌群及免疫功能的影响[J].中国微生态学杂志,2020,32(11):1309-1313.[3]刘冬,林智峰,张珂,等.慢阻肺合并下呼吸道感染患者痰液病原菌分布及血清SAA水平变化分析[J].中国病原生物学杂志,2023,18(12):1443-1447.[4]马雪,寇国先.痰热清联合哌拉西林钠他唑巴坦钠治疗AECOPD的疗效分析[J].检验医学与临床,2021,18(23):3481-3483.[5]文志勇,卢文芬.注射用头孢哌酮钠/舒巴坦钠联用盐酸莫西沙星氯化钠注射液致肝损伤1例[J].中国药物警戒,2019,16(4):253-254.[6]熊小敏,王能勇,吴鹏.莫西沙星序贯疗法在老年下呼吸道感染中的应用及对血清炎症因子的影响[J].中国老年学杂志,2018,38(8):1858-1860.[7]曹媛,吴桂莲.头孢噻肟钠/他唑巴坦钠治疗急性细菌性下呼吸道感染对患者血清PCT、CRP和SAA水平的影响[J].海南医学,2018,29(22):3119-3122.[8]付靖瑜,柯俊,陈伟,等.阿米卡星联合哌拉西林钠/他唑巴坦钠治疗重症肺炎的疗效及对血清HMGB1、sTREM-1、miR-233的影响[J].临床和实验医学杂志,2024,23(13):1376-1381.[9]姬波,李树蕤,关月,等.头孢哌酮钠舒巴坦钠与哌拉西林钠/他唑巴坦钠治疗复杂性尿路感染的安全性与有效性[J].中华医院感染学杂志,2024,34(6):841-846.[10]石羽,曹娟,王红怡,等.哌拉西林钠他唑巴坦钠联合阿奇霉素治疗呼吸道细菌感染的疗效[J].西北药学杂志,2022,37(4):140-144.[11]栾兴龙,孟庆顺,苏峰,等.拉克替醇散联合哌拉西林钠他唑巴坦钠治疗自发性细菌性腹膜炎的临床研究[J].中国医师进修杂志,2022,45(1):42-48.[12]亓玲,魏丽,李静.哌拉西林钠他唑巴坦钠联合布地奈德雾化吸入治疗新生儿肺炎的临床研究[J].中国临床药理学杂志,2023,39(14):1979-1982.[13]胡妮娜,戴文涛,刘娴.痰热清注射液联合哌拉西林钠他唑巴坦钠辅助心理干预治疗急性肺炎临床研究[J].新中医,2020,52(5):65-67.[14]翟静,李向欣,赵鹏程.人免疫球蛋白联合哌拉西林钠他唑巴坦钠治疗重症肺部感染的临床研究[J].现代药物与临床,2018,33(8):1954-1959.[15]王勇飞,朱勤贤,曹旭,等.加味瓜蒌枳实汤联合哌拉西林钠他唑巴坦钠对痰热蕴肺型卒中相关性肺炎患者的免疫功能和血清炎症因子水平的影响[J].中国实验方剂学杂志,2023,29(21):140-146.[16]白植宽.左氧氟沙星联合哌拉西林钠/他唑巴坦钠对支气管扩张症铜绿假单胞菌急性感染者的疗效评估[J].中国微生态学杂志,2018,30(5):560-563.[17]杨媛,凌娜,唐朝政.胸腺肽联合莫西沙星治疗老年慢性阻塞性肺疾病合并重症肺炎的效果[J].中国药物应用与监测,2024,21(4):328-331,380.[18]张番,陈海涛,胡溢,等.莫西沙星溶液雾化吸入配合无创呼吸机治疗慢性阻塞性肺疾病急性加重合并肺部感染的效果[J].临床误诊误治,2024,37(9):71-77.[19]陈建东,黄立,陈凯,等.莫西沙星注射液联合吸入性乙酰半胱氨酸治疗重症肺炎患者的临床研究[J].中国临床药理学杂志,2023,39(7):920-923.[20]刘晓飞,张春艳,贺向红,等.利奈唑胺联合莫西沙星和阿米卡星治疗耐药肺结核的疗效及对血清PON1活性和sTREM-1表达的影响[J].中国医院用药评价与分析,2023,23(9):1075-1078.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(02):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(02):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(02):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(02):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(02):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]何冬兰,李 文.NLR、PLR在慢性阻塞性肺疾病进展、预后中的相关研究[J].医学信息,2022,35(11):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
　HE Dong-lan,LI Wen.Study on Correlation Between NLR and PLR in the Progression and Prognosis of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(02):25.[doi:10.3969/j.issn.1006-1959.2022.11.008]
[10]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(02):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]

更新日期/Last Update: 1900-01-01